In the current study, for all BC subtypes treated with any chemotherapy (Taxane, Ixabepilone, FAC, CMF, FEC, Anthracycline), any endotherapy (Tamoxifen, Aromatase inhibitor), and any anti-HER2 therapy (Trastuzumab, Lapatinib), have shown an increase in the complete pathological response, distant metastasis-free survival, overall survival, disease-free survival, and relapse-free survival of BC patients. Here, ERBB2 is linked to breast cancer.